CN113476526B - A Chinese medicinal composition for treating atrial fibrillation, and its preparation method - Google Patents
A Chinese medicinal composition for treating atrial fibrillation, and its preparation method Download PDFInfo
- Publication number
- CN113476526B CN113476526B CN202110921879.3A CN202110921879A CN113476526B CN 113476526 B CN113476526 B CN 113476526B CN 202110921879 A CN202110921879 A CN 202110921879A CN 113476526 B CN113476526 B CN 113476526B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- atrial fibrillation
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 57
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 11
- 241000255789 Bombyx mori Species 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 241000239226 Scorpiones Species 0.000 claims abstract description 8
- 241000270666 Testudines Species 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 7
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 7
- 241001071917 Lithospermum Species 0.000 claims abstract description 7
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 241000246044 Sophora flavescens Species 0.000 claims description 5
- 241000405414 Rehmannia Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 abstract description 9
- 230000001914 calming effect Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 238000001816 cooling Methods 0.000 abstract description 6
- 230000001788 irregular Effects 0.000 abstract description 4
- 230000002950 deficient Effects 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000010349 pulsation Effects 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract description 2
- 230000006794 tachycardia Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 208000031971 Yin Deficiency Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000001314 paroxysmal effect Effects 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000218202 Coptis Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960003234 amiodarone hydrochloride Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003668 atrial tachycardia Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000013195 electrical cardioversion Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960002443 propafenone hydrochloride Drugs 0.000 description 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound composition with a treatment effect on atrial fibrillation and a preparation method thereof, wherein the traditional Chinese medicine compound composition comprises the following traditional Chinese medicine decoction pieces in parts by mass: 10-20 parts of roasted stiff silkworm, 10-20 parts of scorpion, 5-10 parts of amber powder, 10-20 parts of radix rehmanniae recen, 20-30 parts of ginseng, 10-20 parts of radix sophorae flavescentis, 10-20 parts of salvia miltiorrhiza, 5-10 parts of coptis chinensis, 20-30 parts of roasted turtle shell, 5-10 parts of cinnamon and 10-20 parts of lithospermum. The invention aims at the basic pathogenesis of deficiency of heart-yin and kidney-yin, deficient wind stirring, heart fire internal flaming, wind fire mutual pulsation, qi and yin consumption and palpitation, tachycardia and irregular pulse, establishes the therapeutic principle and treatment method of clearing heart and cooling blood and nourishing yin and calming wind, and provides the traditional Chinese medicine compound which has the effects of clearing heart and cooling blood and nourishing yin and calming wind.
Description
Technical Field
The invention belongs to a traditional Chinese medicine compound composition, and particularly relates to a traditional Chinese medicine compound composition with an atrial fibrillation treatment effect and a preparation method thereof.
Background
Atrial Fibrillation (Atrial Fibrillation) is a clinically common arrhythmia, the incidence of which rapidly increases with age, and is a high risk factor for the increase of the population's all-cause mortality, morbidity and readmission rates. The Framingham research result shows that the accumulated risk of atrial fibrillation of people in 10 years exceeds 15%, the risk of atrial fibrillation is 1.0% in the age group less than 65 years old and is 26.9% in the age group more than 65 years old, and therefore, about 800-1000 ten thousand of patients suffering from atrial fibrillation in China are estimated. The risk of an atrial fibrillation episode, which may induce or aggravate heart failure, is one of the independent risk factors for increased mortality in patients with organic heart disease, mainly results from thromboembolic events and heart failure, especially in patients with organic heart disease. In addition, atrial fibrillation is one of the leading causes of stroke, and in the crowd of 65 years old or older, 1/3's stroke is caused by atrial fibrillation, and the risk of atrial fibrillation patient thromboembolism complication increases 5~ 7 times, and is showing to increase disability rate and lethality rate. With the aging society, the high prevalence of atrial fibrillation, high mortality, and high disability rate create a huge medical burden. Therefore, exploring the mechanism of occurrence of atrial fibrillation, seeking safe and effective early intervention methods, and reducing the onset and recurrence of atrial fibrillation are hot and difficult points in the current cardiovascular disease research field. Unfortunately, since the upstream mechanisms of atrial fibrillation onset are not well understood, there is currently no clear effective primary or secondary prevention of atrial fibrillation attack. Moreover, the long-term effectiveness of atrial fibrillation therapy is limited by the potential side effects of traditional antiarrhythmic drugs, the risk of bleeding from long-term anticoagulation, and the high long-term recurrence rate of radiofrequency ablation.
The traditional Chinese medicine has diagnosis and treatment experience of more than two thousand years aiming at palpitation caused by atrial fibrillation. The advantages of multiple targets and low side reaction of the traditional Chinese medicine meet the requirements of long-range, multiple targets and low side reaction of first-level and second-level prevention and treatment of atrial fibrillation, and the medicine is a treasure house for searching and developing medicines for preventing and treating atrial fibrillation. Aiming at the clinical characteristics of sudden onset of atrial fibrillation, tachycardia and arrhythmia, the applicant provides the pathogenesis recognition of yin deficiency and pneumatosis, wind-fire fighting and qi-yin consumption injury, and adopts corresponding traditional Chinese medicine compound treatment, so that the clinical curative effect is obvious.
Disclosure of Invention
Object of the Invention
Aiming at the difficulty of clinical prevention and treatment of atrial fibrillation, provides a traditional Chinese medicine compound composition which has a treatment effect on atrial fibrillation and has the effects of clearing away heart-fire, cooling blood, nourishing yin and calming endogenous wind and a preparation method thereof.
Adopts the technical proposal
In order to realize the aim, the effective components and the parts by mass of the traditional Chinese medicine compound composition developed by the invention are as follows: 10-20 parts of roasted stiff silkworm, 10-20 parts of scorpion, 5-10 parts of amber powder, 10-20 parts of radix rehmanniae recen, 20-30 parts of ginseng, 10-20 parts of radix sophorae flavescentis, 10-20 parts of salvia miltiorrhiza, 5-10 parts of coptis chinensis, 20-30 parts of roasted turtle shell, 5-10 parts of cinnamon and 10-20 parts of lithospermum.
The preparation method of the traditional Chinese medicine compound composition comprises the following steps: (1) grinding amber into fine powder according to the mass parts; (2) taking the processed stiff silkworm, the scorpion, the dried rehmannia root, the ginseng, the sophora flavescens, the salvia miltiorrhiza, the coptis chinensis, the processed turtle shell, the cinnamon and the lithospermum decoction pieces according to the mass parts, adding water for decocting twice, 1-2 hours each time, combining the decoctions, filtering, concentrating the filtrate, adding ethanol with the volume concentration of 85% for carrying out alcohol precipitation treatment, filtering out precipitates, recovering the filtrate, and concentrating the filtrate at 80 ℃ until the relative density is 1.30-1.36 to obtain an extract; (3) and (3) adding the fine powder obtained in the step (1) into the extract obtained in the step (2). Mixing the obtained extract with pharmaceutically acceptable vehicle, and making into unguent, oral liquid, granule, capsule, tablet or dripping pill.
The invention relates to a traditional Chinese medicine compound composition for treating atrial fibrillation, which is used for determining the treatment principle and treatment method of clearing heart-fire, cooling blood, nourishing yin and stopping endogenous wind aiming at the basic pathogenesis of atrial fibrillation, yin deficiency of heart and kidney, internal stirring of deficient wind, internal flaming of heart fire, mutual pulsation of wind and fire, consumption of qi and yin and irregular pulse. In the formula, the batryticated silkworm is matched with the scorpion to dispel wind and calm convulsion, and the turtle shell nourishes kidney and subdues yang, and the three are combined to play the role of nourishing yin and calming endogenous wind, which is the monarch drug; the coptis root and the sophora flavescens enter heart channels, and the compatibility of the coptis root and the sophora flavescens plays the role of clearing heat and calming heart together, and is taken as a ministerial drug. The ginseng is used for supplementing heart qi, the rehmannia root is used for clearing heat and cooling blood to nourish heart yin, the salvia miltiorrhiza is used for cooling blood and activating blood, and the amber powder is used for calming heart and tranquilizing mind. Cinnamon bark, cortex Cinnamomi, combined with Huang Lian, can communicate heart and kidney and induce fire to return to its original origin. The medicines are used together to play the effects of clearing heart fire, tonifying heart qi, calming heart spirit, nourishing kidney yin, calming deficient wind, relieving palpitation and regulating pulse.
Advantageous effects
The traditional Chinese medicine compound composition can obviously reduce the recurrence frequency and recurrence rate of atrial fibrillation of patients with paroxysmal atrial fibrillation, can obviously improve the clinical symptoms of palpitation, chest distress, dizziness, dry mouth, bitter taste, vexation, feverish palms and soles, spontaneous perspiration or night sweat and the like of the patients with atrial fibrillation, has definite curative effect on treating atrial fibrillation (heart-kidney yin deficiency and heart-fire internal flaming syndrome), and has small toxic and side effects after long-term administration and safe and reliable medication.
Detailed Description
The Chinese medicinal compound composition is applied to treating the symptoms of atrial fibrillation with yin deficiency of heart and kidney and internal flaming of heart fire, and clinically showing palpitation, vexation, dry or bitter mouth, hyperhidrosis, hypodynamia, dizziness, insomnia, red tongue with thin and yellow coating or little coating, fine and rapid pulse irregular pulse and the like.
The specific method comprises the following traditional Chinese medicine decoction piece components in parts by weight: 10-20 parts of roasted stiff silkworm, 10-20 parts of scorpion, 5-10 parts of amber powder, 10-20 parts of radix rehmanniae recen, 20-30 parts of ginseng, 10-20 parts of radix sophorae flavescentis, 10-20 parts of salvia miltiorrhiza, 5-10 parts of coptis chinensis, 20-30 parts of roasted turtle shell, 5-10 parts of cinnamon and 10-20 parts of lithospermum.
The preparation method of the traditional Chinese medicine compound composition comprises the following steps: (1) grinding amber into fine powder according to the mass parts; (2) taking the processed stiff silkworm, the scorpion, the dried rehmannia root, the ginseng, the sophora flavescens, the salvia miltiorrhiza, the coptis chinensis, the processed turtle shell, the cinnamon and the lithospermum decoction pieces according to the mass parts, adding water for decocting twice, 1-2 hours each time, combining the decoctions, filtering, concentrating the filtrate, adding ethanol with the volume concentration of 85% for carrying out alcohol precipitation treatment, filtering out precipitates, recovering the filtrate, and concentrating the filtrate at 80 ℃ until the relative density is 1.30-1.36 to obtain an extract; (3) and (3) adding the fine powder obtained in the step (1) into the extract obtained in the step (2). Mixing the obtained extract with pharmaceutically acceptable vehicle, and making into unguent, oral liquid, granule, capsule, tablet or dripping pill.
The treatment effect of the Chinese herbal compound composition for treating atrial fibrillation according to the present invention is illustrated by the following clinical test examples.
1. Clinical data and methods
57 patients suffering from heart-kidney yin deficiency of atrial fibrillation and heart-fire internal flaming syndrome (14 patients suffering from persistent atrial fibrillation and 43 patients suffering from paroxysmal atrial fibrillation) who are diagnosed in the Xin-Yang medical university affiliated Chinese and western medicine combined hospital and meet the inclusion standard between 2016 and 2021 and 06 months are selected as study objects, and the study objects are divided into 32 traditional Chinese medicines and 25 control groups according to a random digital table method and the tolerance and the taking willingness of the patients to the traditional Chinese medicines.
(1) Diagnostic criteria
Western diagnostic criteria: refer to the AHA/ACC/HRS atrial fibrillation treatment guidelines 2014; the traditional Chinese medicine diagnosis standard is as follows: the diagnosis standard of the syndrome of yin deficiency of heart and kidney and internal flaming of heart-fire is formulated according to the national Standard of the people's republic of China-syndrome part of clinical diagnosis and treatment terminology of traditional Chinese medicine (GB/T16751.2-1997). The main symptoms are: palpitation, chest distress, syncope or dizziness, dry mouth, bitter mouth, vexation and feverish palms and soles. The secondary symptoms are as follows: spontaneous sweating and night sweating. Tongue pulse: red tongue with thin and yellow coating or little coating, thready and rapid pulse or irregular pulse.
(2) Inclusion criteria
The diagnosis standard of the western medicine for atrial fibrillation is met; ② the medicine accords with the diagnosis standard of the deficiency of heart-kidney yin and the internal flaming of heart fire in traditional Chinese medicine; age 30-70 years old; (iv) an electrocardiogram or a dynamic electrocardiogram and the like are recorded in the first 6 months of the group, and the episode of atrial fibrillation is definitely recorded for more than 30 s.
(3) Exclusion criteria
Firstly, atrial fibrillation related to serious valvular heart disease; atrial fibrillation associated with hyperthyroidism; atrial fibrillation is associated with cerebrovascular accident. ② the fraction of the left ventricular ejection is less than 35 percent, and the cardiac function classification of New York is grade III or IV. ③ anticoagulation contraindication. And fourthly, combining thrombus in the left atrium. Sick sinus syndrome, atrioventricular or bundle branch block. Sixthly, the pregnant or nursing women. Seventhly, allergic constitution and allergic to the herbs. Combining patients with serious primary diseases such as cerebrovascular diseases, liver diseases, kidney diseases, hemopoietic system diseases and the like, and patients with mental diseases.
(4) Method of treatment
The traditional Chinese medicine comprises: the Chinese medicinal compound granules are taken by subpackaging 10g per bag, one bag is taken in the morning and evening, and the Chinese medicinal compound granules are dissolved in warm boiled water for 30 minutes after a meal.
And the western medicine control group comprises: the metoprolol sustained-release tablet (Asricon, Sweden, Chinese medicine standard J20150044) is given, 23.75-95 mg.d-1Taking the medicine immediately; or amiodarone hydrochloride tablet (Xenoffy, France, national standard H19993254), 0.2 g. d-1Maintaining the dose, and taking the medicine immediately; or propafenone hydrochloride tablets (Shanghai, China and West three-dimensional pharmaceutical industry Co., Ltd., national Standard H31020452) of 300-600 mg d-1The dosage is maintained, and the oral administration is carried out for 2-3 times.
The treatment course of the two groups is 24 weeks. During the treatment period, basic medicines for treating cardiovascular diseases such as hypertension and dyslipidemia can be applied correspondingly, and other anti-arrhythmia medicines with Chinese and western medicines are forbidden. The acute attack stage is treated by amiodarone or propafenone or electrical cardioversion. If paroxysmal atrial fibrillation lasts for 48 hours, warfarin (Shanghai Xin Ying, Chinese medicine standard H31022123) is administered to both groups, and the dosage is adjusted according to the international standard ratio, so as to maintain the international standard ratio between 2.0 and 3.0, or rivaroxaban tablets (Bayer, Germany, Chinese medicine)Quasi-character J20180076) 15-20 mg.d-1And (4) anticoagulant treatment.
(5) Observation indicator and method
Electrocardiograms and dynamic electrocardiograms were recorded before treatment and every 4 weeks after the start of treatment in both groups. Echocardiography examination was performed before treatment, 24 weeks after treatment.
(ii) recurrence rate and frequency of recurrence of paroxysmal atrial fibrillation the recurrence of paroxysmal atrial fibrillation is defined as a second episode of atrial fibrillation within the observation period. And (3) recording the number of recurrent atrial fibrillation patients in the observation period of two groups of patients with paroxysmal atrial fibrillation by follow-up visit, and calculating the recurrence rate, wherein the recurrence rate is the number of recurrent atrial fibrillation patients, and the number of recurrent atrial fibrillation patients is multiplied by 100%. The number of episodes of atrial fibrillation per relapsing patient during the observation period was defined as the number of relapses.
② the echocardiogram adopts Vivid color Doppler ultrasonic diagnostic apparatus of GE company in America, the probe frequency is 3.5 Hz. The patient takes the left lateral decubitus and collects the long axis, the short axis (the level of the mitral valve, the level of papillary muscle and the level of the apex of the heart) and the apex (the level of the two-cavity, three-cavity and four-cavity heart) two-dimensional ultrasonic sections of the left ventricle beside the sternum. Left ventricular end-diastolic measurement (LAD), Left Ventricular Ejection Fraction (LVEF), Left ventricular end-diastolic measurement (LVEDD) were obtained from a parasternal Left ventricular long axis section.
③ the clinical curative effect judgment standard shows the effect: paroxysmal AF does not occur at all or occasionally occurs, and persistent AF repeats or becomes paroxysmal AF occasionally occurring; or the ventricular rate is less than 80 times/min in a resting state. The method has the following advantages: paroxysmal AF outbreaks are reduced by more than 60 percent, the time of the outbreaks and the frequency of the outbreaks are included, and the persistent AF is converted into the paroxysmal AF; or the ventricular rate is less than 90 times/min in a resting state. And (4) invalidation: those who do not meet the above criteria of effectiveness or effectiveness.
The standard of the curative effect of the syndrome of the traditional Chinese medicine is formulated according to the guiding principle of clinical research of new traditional Chinese medicines, the integral method is adopted, the main symptoms are respectively scored as 0, 2, 4 and 6 according to the absence, lightness, middle and weight of symptoms, the secondary symptoms are respectively scored as 0, 1, 2 and 3 according to the absence, lightness, middle and weight of symptoms, and the tongue and pulse conditions are respectively scored as 0 and 1 according to the normality and abnormality. Efficacy index is (pre-treatment total score-post-treatment total score) ÷ pre-treatment total score. The curative effect is judged according to the following standards: the method has the following advantages: the symptoms are obviously improved, and the syndrome score is reduced by more than or equal to 70 percent compared with the syndrome score before treatment; secondly, the method is effective: the symptoms are improved, and the syndrome score is reduced by more than or equal to 30 percent and less than 70 percent compared with the syndrome score before treatment; ③ invalid: symptoms are not improved, and the syndrome score is reduced by less than 30 percent compared with the syndrome score before treatment; weighting: the symptoms worsen, and the syndrome score decreases by less than 0% compared with the former.
(6) Statistical method
Statistical analysis is carried out on the collected data by adopting SPSS 21 statistical software, and if the measured data conforms to normal distribution, the mean value plus or minus standard deviation is used
In this case, the paired sample t test was used for the intra-group comparison, and the independent sample t test was used for the inter-group comparison. Expressing the data rate and composition ratio by using χ2And (6) checking. The difference is statistically significant when P is less than 0.05.
2. Results
(1) The traditional Chinese medicine compound composition can reduce the recurrence frequency and recurrence rate of patients with paroxysmal atrial fibrillation
The relapse number and the relapse rate of the traditional Chinese medicine paroxysmal atrial fibrillation patients are lower than those of a control group, and the statistical difference is realized (P is less than 0.05). The relapse frequency of the traditional Chinese medicine group is obviously lower than that of the control group, and the difference has statistical significance (P is less than 0.05). The results are shown in Table 1.
TABLE 1 comparison of frequency and rate of recurrence in two groups
Note: x channel X2Inspection, χ25.204, P < 0.05; compared with the control group, the compound of the formula,#P＜0.05
(2) the clinical curative effect and the traditional Chinese medicine syndrome curative effect of the traditional Chinese medicine compound composition are obviously superior to those of pure western medicine treatment
The clinical total effective rate of the traditional Chinese medicine is superior to that of a control group, the difference has statistical significance, and the result is shown in a table 2; the total effective rate of the traditional Chinese medicine symptoms of the traditional Chinese medicine group is obviously superior to that of the control group, the difference has statistical significance, and the result is shown in table 3.
TABLE 2 two groups of clinical efficacy comparison/example
Note: jingchi type2Inspection, χ2＝4.131，P＜0.05
TABLE 3 two comparative/examples of the curative effects of TCM syndrome
Note: jingchi type2Inspection, χ2＝5.027，P＜0.05
(3) The traditional Chinese medicine compound composition can obviously reduce the single syndrome integral of the traditional Chinese medicine principal symptoms
After the treatment of the traditional Chinese medicine group, the score of the main symptoms such as palpitation, chest distress, dizziness, dry mouth, bitter taste in mouth, vexation, feverish palms and soles, spontaneous perspiration or night sweat, tongue pulse and the like are all obviously reduced (P is less than 0.05 or P is less than 0.01), and after the treatment of the control group, the score of the main symptoms except the score of the palpitation and the chest distress is reduced, and the score of the main symptoms has no obvious change. The score of the main symptoms of the two groups after treatment is compared, and the score of the main symptoms of the traditional Chinese medicine except palpitation is lower than that of a control group (P is less than 0.05 or P is less than 0.01). The results are shown in Table 4.
TABLE 4 comparison of single syndrome before and after treatment
Note: group comparisons,. P < 0.01; comparison between groups # P < 0.01, # # P < 0.05.
(4) The traditional Chinese medicine compound composition can improve partial cardiac function parameters
LVEDD before and after treatment of the traditional Chinese medicine and the control group is obviously reduced, the difference has obvious statistical significance (P is less than 0.01), and no obvious statistical difference exists between the groups; comparison differences between before and after treatment and between the LAD and LVEF groups were not statistically significant, and the results are shown in Table 5.
TABLE 5 comparison of two sets of cardiac function parameters
Note: the comparison is carried out in the group,**P＜0.01。
Claims (3)
1. the traditional Chinese medicine compound composition with the effect of treating atrial fibrillation is characterized by comprising the following components in parts by mass: 10-20 parts of roasted stiff silkworm, 10-20 parts of scorpion, 5-10 parts of amber powder, 10-20 parts of radix rehmanniae recen, 20-30 parts of ginseng, 10-20 parts of radix sophorae flavescentis, 10-20 parts of salvia miltiorrhiza, 5-10 parts of coptis chinensis, 20-30 parts of roasted turtle shell, 5-10 parts of cinnamon and 10-20 parts of lithospermum.
2. The compound Chinese medicinal composition for treating atrial fibrillation according to claim 1, wherein the preparation method comprises the following steps: (1) grinding amber into fine powder according to the mass parts; (2) taking the processed stiff silkworm, the scorpion, the dried rehmannia root, the ginseng, the sophora flavescens, the salvia miltiorrhiza, the coptis chinensis, the processed turtle shell, the cinnamon and the lithospermum decoction pieces according to the mass parts, adding water for decocting twice, 1-2 hours each time, combining the decoctions, filtering, concentrating the filtrate, adding ethanol with the volume concentration of 85% for carrying out alcohol precipitation treatment, filtering out precipitates, recovering the ethanol from the filtrate, and concentrating the filtrate at 80 ℃ until the relative density is 1.30-1.36 to obtain an extract; (3) and (3) adding the fine powder obtained in the step (1) into the extract obtained in the step (2), and preparing the mixture and a pharmaceutically acceptable carrier into a medicament in the dosage form of paste, oral liquid, granules, capsules, tablets or pills.
3. The traditional Chinese medicine compound composition of claim 1 is prepared into a medicament in the dosage form of paste, oral liquid, granules, capsules, tablets or pills according to the method of claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110921879.3A CN113476526B (en) | 2021-08-12 | 2021-08-12 | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110921879.3A CN113476526B (en) | 2021-08-12 | 2021-08-12 | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113476526A CN113476526A (en) | 2021-10-08 |
| CN113476526B true CN113476526B (en) | 2022-03-29 |
Family
ID=77945070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110921879.3A Active CN113476526B (en) | 2021-08-12 | 2021-08-12 | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476526B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422562A (en) * | 2007-10-29 | 2009-05-06 | 辽宁中医药大学附属医院 | Medicine for treating premature beat and atrial fibrillation |
-
2021
- 2021-08-12 CN CN202110921879.3A patent/CN113476526B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113476526A (en) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017005220A1 (en) | Chinese medicine composition for treating arrhythmia and manufacturing method thereof | |
| CN101278939B (en) | Medicament composition for curing cardiovascular and cerebrovascular diseases and method of preparing the same | |
| CN107648479B (en) | Traditional Chinese medicine formula for treating hypertension and product thereof | |
| CN113476526B (en) | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method | |
| CN113559206B (en) | Compound traditional Chinese medicine for preventing and treating atrial fibrillation | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| WO2019153817A1 (en) | Traditional chinese medicine composition for treating hypertensive heart failure | |
| CN112716998A (en) | Traditional Chinese medicine preparation for treating pulmonary hypertension | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN115120671B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia and application thereof | |
| CN116808162B (en) | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof | |
| CN115814020B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof | |
| CN114796420B (en) | Traditional Chinese medicine composition for treating non-valvular atrial fibrillation as well as traditional Chinese medicine preparation and application thereof | |
| CN115177691B (en) | Traditional Chinese medicine composition for treating ventricular premature beat and application thereof | |
| CN106176963A (en) | A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101607070B (en) | Pharmaceutical composition for treating heart cerebrovascular disease | |
| CN116135216B (en) | Traditional Chinese medicine composition for treating cervical abscess type lymph node tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |